OINDPnews


H&T Presspart banner

Business

Herantis partners with Nanoform on intranasal biologics formulation projects

Herantis Pharma has signed an agreement with nanoparticle technology company Nanoform Finland to try out Nanoform's biologics nanoparticle technology for intranasal formulations of CDNF (cerebral dopamine neurotrophic factor). Nanoform launched its nanoparticle technology for biologics in November 2020. Herantis is developing CDNF for the treatment of Parkinson’s … [Read more...] about Herantis partners with Nanoform on intranasal biologics formulation projects

AuraVax licenses intranasal vaccine technology from University of Houston

AuraVax Therapeutics, which is developing an intranasal vaccine against COVID-19, announced that it has acquired an exclusive license for IP related to intranasal respiratory vaccine technology and STING agonist technology from the University of Houston. Earlier this year, the company announced that it had licensed liposomal STING agonist technology from Massachusetts … [Read more...] about AuraVax licenses intranasal vaccine technology from University of Houston

Revelation Biosciences raises $4.4 million for development of REVTx‑99 intranasal PHAD

Revelation Biosciences said that it has closed a private placement financing with gross proceeds of $4.4 million that it plans to use for development of two pipeline products, including its REVTx-99 intranasal phosphorylated hexaacylated disaccharide (PHAD). REVTx-99 is in development for the treatment of viral respiratory infections, including COVID-19.  In … [Read more...] about Revelation Biosciences raises $4.4 million for development of REVTx‑99 intranasal PHAD

Noveome partners with Walter Reed Army Institute of Research on preclinical study of intranasal ST266 secretome

Noveome Biotherapeutics has signed a research and development agreement with Walter Reed Army Institute of Research (WRAIR) regarding preclinical studies of an intranasal formulation of Noveome's ST266 secretome, the company said. Under the agreement, WRAIR Branch Chief Deborah Shear will evaluate intranasal ST266 in animal models of traumatic brain injury (TBI), with … [Read more...] about Noveome partners with Walter Reed Army Institute of Research on preclinical study of intranasal ST266 secretome

US Department of Defense provides up to $6 million for Phase 2 trials of PUL-042 inhalation solution for the treatment of COVID-19

According to Pulmotect, the US Department of Defense has provided a grant worth up to $6 million for the completion of two Phase-2 clinical trials of the company's PUL-042 immunostimulant inhalation solution for the prevention and treatment of COVID-19. In May 2020, Pulmotect announced that it had gotten FDA permission for the two trials. The studies, which both … [Read more...] about US Department of Defense provides up to $6 million for Phase 2 trials of PUL-042 inhalation solution for the treatment of COVID-19

Pneumagen raises £2.5 million for clinical development of Neumifil nasal spray against flu, RSV, and COVID-19

University of St Andrews spin out Pneumagen said that it has raised £2.5 million for clinical development of its Neumifil intranasal carbohydrate binding module (mCBM) for the prevention and treatment of respiratory viruses, including flu, RSV, and COVID-19. The company says that it previously raised £4 million investment for development of Neumifil, which is … [Read more...] about Pneumagen raises £2.5 million for clinical development of Neumifil nasal spray against flu, RSV, and COVID-19

UC Davis spin out InVixa to develop inhaled statins for the treatment of COVID-19

A new spin out from the University of California, Davis called InVixa announced that it has acquired the rights to UC Davis intellectual property related to delivery of statins to the lung for the treatment of viral respiratory infections, including COVID-19. InVixa said that it expects to select a lead candidate following pre-clinical studies early this year and … [Read more...] about UC Davis spin out InVixa to develop inhaled statins for the treatment of COVID-19

Odyssey acquired intranasal therapy for the treatment of mild traumatic brain injury from Prevacus

Odyssey Group International said that it has signed a definitive agreement with Prevacus to acquire PRV-002, an intranasal therapy for the treatment of mild traumatic brain injury. As part of the deal, Prevacus CEO Jake Vanlandingham will join Odyssey. In 2017, Prevacus announced that it planned to initiate a Phase 1 trial of PRV-002; however, Prevacus has been … [Read more...] about Odyssey acquired intranasal therapy for the treatment of mild traumatic brain injury from Prevacus

AuraVax Therapeutics licences intranasal vaccine adjuvant technology from Massachusetts General Hospital

Intranasal vaccine developer AuraVax Therapeutics said that the company has licensed liposomal STING agonist technology from Massachusetts General Hospital (MGH) for use as an adjuvant in vaccines against COVID-19 and other respiratory diseases. The technology was developed by MGH researcher Mei X. Wu. AuraVax co-founder Navin Varadarajan commented, "We are … [Read more...] about AuraVax Therapeutics licences intranasal vaccine adjuvant technology from Massachusetts General Hospital